Skip to content

Clinical trials

Major Depressive Disorder trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Major Depressive Disorder Country / region: France Clear all

125 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20041
20052
20066
20078
20084
20095
20104
20116
20126
20134
20143
20151
20166
20179
20187
20195
20204
20213
20227
20237
20249
202510
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed74
Recruiting20
Unknown status12
Terminated10
Not yet recruiting4
Active, not recruiting2
Suspended2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company9
H. Lundbeck A/S9
Janssen Research & Development, LLC8
University Hospital, Montpellier7
Assistance Publique - Hôpitaux de Paris6
Centre Hospitalier Esquirol6
Sanofi6
Otsuka Pharmaceutical Development & Commercialization, Inc.4
Rennes University Hospital4
Assistance Publique Hopitaux De Marseille3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Major Depressive Disorder125
Depressive Disorder22
Bipolar Disorder12
Mood Disorders7
Mental Disorders6
Schizophrenia6
Depressive Disorder, Treatment-Resistant4
Anhedonia3
Anxiety Disorders3
Pain3

Trials

Showing 76 to 100 of 125. Each trial links to its page on Pharma Observatory.

25 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.